Seres Therapeutics, Inc. (MCRB) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This Quarterly Report covers the period ended September 30, 2024. Seres Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on live biotherapeutics. The quarter was defined by the completion of the sale of its VOWST microbiome therapeutic business to Société des Produits Nestlé S.A. (SPN) on September 30, 2024. Consequently, the VOWST business is now classified as discontinued operations. The company's remaining focus is on the development of SER-155 for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and other cultivated live biotherapeutic candidates.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue (Continuing Ops) | $0 | $0 | $0 | $0 |
| Net Loss from Continuing Ops | $(51.0) million | $(41.0) million | $(110.1) million | $(155.4) million |
| Net Income (Loss) from Discontinued Ops | $139.8 million | $(6.8) million | $125.9 million | $82.9 million |
| Total Net Income (Loss) | $88.8 million | $(47.9) million | $15.8 million | $(72.5) million |
| Cash and Cash Equivalents | $66.8 million | $127.9 million (Dec 31, 2023) | $66.8 million | $127.9 million (Dec 31, 2023) |
| Operating Cash Flow (Continuing) | Not provided for 3 months | Not provided for 3 months | $(109.7) million | $(69.9) million |
| Accumulated Deficit | $(962.5) million | $(937.0) million (Dec 31, 2023) | $(962.5) million | $(937.0) million (Dec 31, 2023) |
Note: Figures in millions. Discontinued operations results include a $146.7 million gain on the sale of the VOWST business.
Material Changes vs. Prior Period
- Transaction Completion: The sale of the VOWST business to SPN closed on September 30, 2024. This resulted in a one-time pre-tax gain of $146.7 million, driving the net income for the quarter and year-to-date despite significant operating losses from continuing operations.
- Debt Extinguishment: The company fully repaid its Oaktree Term Loan facility ($110 million principal) using proceeds from the transaction. This resulted in a $23.4 million loss on extinguishment of debt recorded in Q3 2024.
- Expense Reduction: Operating expenses for continuing operations decreased significantly compared to the prior year due to a restructuring plan implemented in late 2023. Research and Development (R&D) expenses for the nine months ended September 30, 2024, were $51.8 million, down from $94.6 million in the prior year period. General and Administrative (G&A) expenses were $40.7 million, down from $63.5 million.
- Capital Structure: SPN purchased 14.3 million shares of common stock for $15.0 million as part of the transaction. The company also raised approximately $21.8 million net through its "at-the-market" equity offering program during the nine-month period.
Guidance, Outlook, and Risks
- Going Concern: Management has identified conditions that raise substantial doubt about the company's ability to continue as a going concern for 12 months from the issuance date. The company expects to require additional funding by the fourth quarter of 2025 to support operations and obligations related to the transaction.
- Transaction Consideration: Future cash flows depend on contingent payments from SPN, including $50 million in January 2025 and $25 million in July 2025 (Installment Payments), which are conditioned on material compliance with a Transition Services Agreement (TSA). There are also potential milestone payments totaling up to $275 million based on VOWST sales targets, though these are subject to set-off against a prepaid milestone.
- Nasdaq Compliance: The company received notice from Nasdaq on November 7, 2024, that its stock price had closed below the $1.00 minimum bid price requirement for 30 consecutive business days. It has an initial 180-day compliance period to regain compliance, potentially requiring a reverse stock split.
- Development Outlook: The company is advancing SER-155, which recently completed a Phase 1b study showing significant reduction in bloodstream infections in allo-HSCT patients. No specific financial guidance was provided for future periods.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $66.8 million cash balance against the projected burn rate and the timing of the contingent $75 million installment payments from SPN.
- TSA Compliance: Assess the company's ability to meet the material compliance obligations under the Transition Services Agreement to secure the $75 million in installment payments.
- Going Concern Status: Monitor management's plans to secure additional financing before Q4 2025, as the filing explicitly states substantial doubt regarding the ability to continue as a going concern.
- Nasdaq Listing: Track the stock price to determine if a reverse stock split or transfer to the Nasdaq Capital Market will be necessary to avoid delisting by May 6, 2025.
- Discontinued Operations: Confirm that future financial statements will exclude VOWST revenue and expenses, focusing solely on the development costs of SER-155 and other pipeline candidates.